Author

Ramon Garcia

Institution: Metrum Research Group (United States)

Observed institution: Metrum Research Group (United States)

ORCID: 0000-0003-3223-8251

Observed ORCID: 0000-0003-3223-8251

OpenAlex ID: A5009162754

A model‐based analysis to guide gonadotropin‐releasing hormone receptor antagonist use for management of endometriosis

2021 · Oliver Pohl, Kyle Baron, et al. · British Journal of Clinical Pharmacology · 13

Model‐based meta‐analysis using latent variable modeling to set benchmarks for new treatments of systemic lupus erythematosus

2023 · Kosalaram Goteti, Ramon Garcia, et al. · CPT Pharmacometrics & Systems Pharmacology · 11

Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient‐level placebo ( Standard‐of‐Care ) data to enable model‐informed drug development

2022 · Kosalaram Goteti, Jonathan French, et al. · CPT Pharmacometrics & Systems Pharmacology · 11

Population Pharmacokinetic/Pharmacodynamic and Exposure–Response Modeling of Garadacimab in Healthy Volunteers and Patients With Hereditary Angioedema

2025 · Ramon Garcia, Shen Cheng, et al. · CPT Pharmacometrics & Systems Pharmacology · 7

Bayesian sparse regression for exposure–response analyses of efficacy and safety endpoints to justify the clinical dose of valemetostat for adult T‐cell leukemia/lymphoma

2024 · Masato Fukae, James Rogers, et al. · CPT Pharmacometrics & Systems Pharmacology · 6

Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T–Cell Lymphoma

2025 · Hiroyuki Inoue, Xiaoning Wang, et al. · The Journal of Clinical Pharmacology · 2

Exposure–Response Relationships in Patients with Non‐Small‐Cell Lung Cancer and Other Solid Tumors Treated with Patritumab Deruxtecan (HER3‐DXd)

2025 · Li Li, Mark Lee, et al. · Clinical Pharmacology & Therapeutics · 1

Exposure-response (ER) analyses of efficacy and safety of trastuzumab deruxtecan (T-DXd) to inform dosing recommendation in HER2-mutant non-small cell lung cancer (NSCLC).

2024 · Amit Khatri, Daniel Polhamus, et al. · Journal of Clinical Oncology · 1

Response to Comment on “Population Pharmacokinetics of Valemetostat and Exposure–Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T‐Cell Lymphoma”

2025 · Hiroyuki Inoue, Xiaoning Wang, et al. · The Journal of Clinical Pharmacology

Population Pharmacokinetic and Exposure-Response Modelling Analyses to Support Valemetostat Dose Recommendations in Patients With Relapsed/Refractory (R/R) Peripheral T-cell Lymphoma (PTCL)

2025 · Hiroyuki Inoue, Xiaoning Wang, et al. · American Conference on Pharmacometrics (ACoP)

Works count: 10

Citation count: 52

H-index: 5

I10-index: 3